The interaction between nirmatrelvir/ritonavir and sirolimus: a case report of a kidney recipient with renal insufficiency and COVID-19
Nirmatrelvir/ritonavir is a novel drug combination authorized by the US Food and Drug Administration for the treatment of coronavirus disease 2019 (COVID-19). This report describes the case of a patient with a prior history of kidney transplantation who received nirmatrelvir/ritonavir. In this case,...
Saved in:
Main Authors: | Yinhua Gong, Dan Shen, Jinfang Shi, Ye Jiang, Jie Gao |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-01-01
|
Series: | Journal of International Medical Research |
Online Access: | https://doi.org/10.1177/03000605241307845 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS.
by: Ji Sun, et al.
Published: (2024-01-01) -
Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
by: Alison K. Cohen, et al.
Published: (2025-01-01) -
Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes
by: Guanyue Su, et al.
Published: (2025-02-01) -
Stability indicating RP-HPLC technique for simultaneous estimation of nirmatrelvir and ritonavir in their new copackaged dosage form for COVID-19 treatment
by: Mohamed G. Yassin, et al.
Published: (2025-01-01) -
Conversion to Sirolimus Therapy in Kidney Transplant Recipients with New Onset Diabetes Mellitus after Transplantation
by: Massimiliano Veroux, et al.
Published: (2013-01-01)